Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 14/20 | 0.40 |
| ▸ | MMP3 | P08254 | 10/20 | 0.40 |
| ▸ | PDE4A | P27815 | 6/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.40 |
| ▸ | MMP1 | P03956 | 6/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7512119 | 0.84 | FKBP1A (0.41) | MMP2MMP3PDE4APDE4BPDE4C | |
| SCHEMBL7080521 | 0.82 | MMP1 (0.41) | MMP2MMP3PDE4APDE4BPDE4C | |
| SCHEMBL7079276 | 0.75 | MMP2 (0.52) | MMP2MMP3PDE4APDE4BPDE4C | |
| SCHEMBL7073432 | 0.68 | MMP2 (0.60) | MMP2MMP3PDE4APDE4BPDE4C | |
| SCHEMBL7079189 | 0.66 | MMP1 (0.44) | MMP2MMP3PDE4APDE4BPDE4C | |
| SCHEMBL8002828 | 0.65 | MMP2 (0.57) | MMP2MMP3PDE4APDE4BPDE4C | |
| SCHEMBL7080932 | 0.65 | MMP2 (0.57) | MMP2MMP3PDE4APDE4BPDE4C | |
| SCHEMBL4290067 | 0.64 | MMP2 (0.41) | MMP2MMP3MMP1FKBP1A | |
| SCHEMBL7074155 | 0.64 | MMP2 (0.62) | MMP2MMP3PDE4APDE4BPDE4C | |
| SCHEMBL10419532 | 0.64 | PDE4A (0.53) | MMP2MMP3PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030207889-A1 | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | OWEN DAVID ALAN (GB) | 2003-11-06 | — | — | US | disclosed |
| US-6566384-B1 | For therapy of cancer, inflammation and inflammatory diseases, tissue degeneration, periodontal disease, ophthalmological disease, dermatological disorders, fever, cardiovascular effects, haemorrhage, coagulation and acute phase response | DARWIN DISCOVERY LTD. (GB) | 2003-05-20 | — | — | US | disclosed |
| US-6118001-A | ANTICANCER AGENT; ANTIARTHRITIC AGENT | DARWIN DISCOVERY, LTD. (GB) | 2000-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207889-A1 | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | MMP13, MMP2, MMP9 | MMP2 2/4885MMP3 5/4885PDE4A 3341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.